Fisher & Paykel Healthcare first-half performance

Fisher & Paykel Healthcare (ASX:FPH) announced a record first-half revenue of $951.2 million for the 2025 financial year. This represents an 18% rise from the prior period. The net profit after tax increased by 43% to $153.2 million, driven by new product launches and high demand in hospitals.

Fisher & Paykel Healthcare future outlook

Fisher & Paykel Healthcare reported significant growth in its first-half financial results for FY2025, with an 18% rise in revenue and a 43% increase in net profit. The company's performance was bolstered by new product introductions, an expanded market presence, and improvements in operational efficiency. The hospital product group saw a 21% revenue increase, while the homecare segment grew by 14% due to strong demand for OSA masks and accessories. Looking forward, the company maintains its full-year guidance, anticipating operating revenue between $1.9 billion and $2.0 billion, and net profit after tax ranging from $320 million to $370 million. Strategic developments include the opening of a new manufacturing facility in Guangzhou, China, and continued investment in R&D, which accounts for 12% of revenue. Fisher & Paykel Healthcare is optimistic about sustaining growth through innovation and market expansion.

Executive insights on financial performance

Our record revenue and profit in the first half reflect the successful introduction of new products and changes in clinical practice that have driven increased demand, particularly in our hospital product group. We remain committed to our strategic initiatives and investment in R&D to continue delivering innovative solutions to our customers.